This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Arvinas ER chimeric degrader, ARV-471, is an oral, bioavailable ER degrading CRBN-based PROTAC for the treatment of patients with…
molecule
1 year ago ●
2 mins read
Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which received emergency use authorization from the FDA…
molecule
1 year ago ●
3 mins read
MRTX1133 was nominated as December 2021’s cover molecule by reviewers Joachim Rudolph and Julien Lefranc. MRTX1133 is a non-covalent inhibitor…
molecule
1 year ago ●
2 mins read
CC-90001 was nominated by reviewer Christian Kuttruff. CC-90001 is a JNK (c-Jun N-Terminal Kinase) inhibitor and a Phase II clinical…
molecule
1 year ago ●
2 mins read
Mutated Huntingtin (HTT) protein is the cause of Huntington’s disease (HD). HTT-D3 is an oral, CNS-penetrant molecule with human HTT…
molecule
1 year ago ●
2 mins read
Ulotaront (SEP-363856) is a Phase III candidate with FDA Breakthrough Therapy Designation for the treatment of schizophrenia with demonstrated efficacy…
molecule
1 year ago ●
2 mins read
Load More
